

WEDNESDAY 11th JUNE 2014 COMMENCING 9.30 AM
AT CARDIFF METROPOLITAN UNIVERSITY, LLANDAFF
CAMPUS, WESTERN AVENUE, CARDIFF CF5 2YB

AGENDA

- | | | |
|----|------------------------------------|------------------|
| | | Enclosure |
| 1. | Welcome and introduction | |
| 2. | Apologies | |
| 3. | Declarations of interest | |
| 4. | Minutes of previous meeting | 1/AWMSG/0614 |

To protect commercial confidentiality, the morning session of four appraisals will be conducted in private. The final appraisal recommendations will be announced in public after the lunch break

- | | | |
|----|--|----------------------------|
| | | |
| 5. | Appraisal 1 - Full Submission (WPAS)
Insulin degludec (Tresiba[®]) for the treatment of diabetes mellitus in adults | 2/AWMSG/0614
Appendices |
| 6. | Appraisal 2 - Full Submission (WPAS)
Velaglucerase alfa (VPRIV[®]) for long-term enzyme replacement therapy in patients with type 1 Gaucher disease | 3/AWMSG/0614
Appendices |
| 7. | Appraisal 3 - Full Submission (PAS)
Eltrombopag (Revolade[®]) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy | 4/AWMSG/0614
Appendices |
| 8. | Appraisal 4 - Full Submission (PAS)
Abiraterone acetate (Zytiga[®]) in combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated | 5/AWMSG/0614
Appendices |

The meeting will now open to the public (approx 2.00pm)

9. **Chairman's report (verbal update)**
10. **National Prescribing Indicators 2013–2014: Analysis of Prescribing Data to December 2013** 6/AWMSG/0614
11. **Feedback from AWPAG Meeting 12th March 2014** 7/AWMSG/0614
12. **Appraisal 5 - Full Submission** 8/AWMSG/0614
Imatinib (Glivec®) as adjuvant treatment, for up to 36 months, of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment Appendices
13. **Appraisal 6 – Limited Submission** 9/AWMSG/0614
Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) for antiretroviral treatment-experienced adults infected with human immunodeficiency virus type 1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load $\leq 100,000$ HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera Appendices

Date of next meeting:
Wednesday 16th July 2014 in Cardiff